I have a question about the pricing of treatments. We see the figure “US$150,000” often used. No doubt there would be Govt subsidies to allow people access to a drug without actually paying that amount. Mostly in “First World” countries (Australia, USA, Canada etc).
But what about countries that can’t afford that? Would drug companies “scale” the price down to reflect nation’s ability to pay? This would increase market penetration but at a lower yield. But, importantly, patients would get treatment.
PYC - General Discussion, page-32
-
- There are more pages in this discussion • 370 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.010(10.0%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 11.0¢ | 10.0¢ | $184.6K | 1.761M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 51807 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 680221 | 5 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| PYC (ASX) Chart |